Emerging retatrutide, a combined-action drug targeting simultaneously GLP-1 and GIP receptors, is sparking considerable excitement within the weight loss community. Initial clinical trials have revealed substantial decreases in body mass and advancements in physiological markers for people with obesity . Scientists believe this novel approach co… Read More